Results: With Cobe Spectra apheresis machine it was possible to process larger blood volumes per procedure with higher CD34+ cell collection effi ciency (p = 0.0229) and lower RBC contamination of the harvest than with Amicus (p = 0.0116). On the other hand, Amicus helped to limit PLT contamination of the harvest (p < 0.0001), thus minimizing post-procedural decrease in patient´s PLT count. The highest detected advantage of CVC usage was higher fl ow rate of procedure, thus processing larger blood volumes per unit of time. Interesting fi nding was the tendency to lower harvest PLT contamination (p = 0.054). When LVL was performed, signifi cantly higher HSCs yields were collected, even in "poor mobilizers" when the pre-run parameters were low. Conclusion: Management of PBSC collection requires a particular approach in each subject. Institutionally and individually optimized collection may help to improve the transplantation outcome and decrease the fi nancial costs (Tab. 8, Ref. 15). Text in PDF www.elis.sk.
Stem cells are unspecialized cells in the human body that are able to develop into specialized cells after recieving the right signal. Hematopoietic stem/progenitor cells (HSCs) are capable to maintain hematopoiesis and to differentiate into all mature peripheral blood cells. Any procedure, where HSCs of any donor and any source are given to a recipient with intention to replace the hematopoietic system in total or in part, is called hematopoietic stem/progenitor cells transplantation. Its development has revolutionized health care, particularly in hematology and oncology. Autologous and allogeneic HSCs transplants have been increasingly performed as an effective curative treatment modality in a variety of disorders, including leukemia, lymphoma, multiple myeloma, bone marrow (BM) failure syndromes, immunodefi ciency and genetic disorders.
Transplantation outcome and costs depend, besides other factors, also from the graft characteristics. Suffi cient number of good quality HSCs is necessary to ensure a reliable hematopoietic regeneration. A common marker used to identify HSCs in peripheral blood or in the graft is CD34 antigen found on their surface and detected by fl ow cytometry. Another approach to assess HSCs yield are the in-vitro assays (e.g. CFU -Colony-forming units). However, since CFU assessment takes time, its predictive value for engraftment is more useful in autologous setting, when the cells are planned to be transplanted later. HSCs target dose for transplantation differs according to clinical situation. In autologous setting, most reports suggest an optimal target dose of 5×10 6 CD34+ cells per kilogram of patient´s body weight, but with 2×10 6 CD34+ cells/kg acceptable engraftment was attained as well (10, 12) . Thus, most centres respect the dose of 2×10 6 CD34+ cells/ kg as the minimum threshold for autologous transplantation. In allogeneic setting, most centres respect the dose of 3×10 6 CD34+ cells/kg as the minimum threshold for transplantation. However, higher cell doses (≥5×10 6 CD34+ cells/kg) are associated with better survival, better engraftment and lower costs of post-transplantation care (8) . In haplotype mismatched transplants, doses of ≥10×10 6 CD34+ cells/kg are used. Historically, HSCs were harvested from BM. The number of human BM transplantations reached peak in the late 1990´s. Afterwards, it has has been declining due to its replacement by alternative HSCs sources, such as peripheral blood and umbilical cord blood. Peripheral blood represents the currently preferred source of HSCs for transplantation (peripheral blood hematopoietic stem/ progenitor cells -PBSC). Before the collection (leukapheresis performed by means of apheresis machine) starts, a substantial increase in number of circulating PBSC is needed. Pharmacologically enhanced recruitment of HSCs into peripheral blood is called "mobilization". Classical mobilization strategies include administration of G-CSF (Granulocyte colony-stimulating factor, fi lgrastim) alone, or in combination with myelosuppressive chemotherapy (CHT+G-CSF). Unfortunately, the "responsiveness" to standard mobilization regimens varies among individuals. G--CSF based mobilization regimens have a 5 % failure rate among healthy donors, cca 30 % among patients, and up to 60 % in high--risk patients such as those exposed to fl udarabine (6, 7, 9, 15) . In particular, patients with advanced hematological disorders and malignancies are often "poor mobilizers".
Hence, the ability to collect suffi cient number of HSCs is infl uenced by various factors. They can be divided in two groups: variables affecting mobilization and variables affecting apheresis collection. Variables af fecting mobilization can be "patient/donor related" (e.g. age, gender, body weight, etc), "disease related" (e.g. diagnosis), "therapy related" (e.g. number and composition of previous CHT cycles, radiotherapy, etc), "mobilization regimen related" (e.g. regimen type, mobilization agents used, dosage, etc) and other. Variables affecting apheresis collection, so called "procedure related variables", include venous access, apheresis device and apheresis regimen used.
In this study, several factors possibly affecting collection outcome were analysed with the objective to develop recommendations for collection practice at the site, in order to increase collection effi cacy, improve the patient´s outcome and decrease fi nancial costs.
Material and methods

Data collection
During the studied period (January 2008 -December 2011), totally 169 collection procedures were performed at the Department of Haematology and Transfusiology in St Cyril and Method Hospital in Bratislava in 126 subjects (50 healthy donors and 76 patients with diagnosis of multiple myeloma, acute leukemia and lymphoma) (Tab. 1). All healthy donors were HLA-identical with recipient (10/10 match). Data were collected retrospectively (January 2008 -August 2008) and prospectively (September 2008 -December 2011). Pre-run parameters in peripheral blood, collection and product characteristics were evaluated after every single collection procedure. Patients and healthy donors gave written informed consent with anonymous data collection and their further statistical analysis. An overview of collected data is shown in Table 2 .
Apheresis technique
Apheresis collection procedures were initiated when the CD34+ cell count in peripheral blood reached at least 10×10 6 /L, with exception of some patients who seemed to be diffi cult to mobilize, when the collection was started earlier. A maximum of two apheresis procedures per mobilization attempt were performed in each subject. Periferal venous access was preferred. If this was not adequate to ensure constant inlet blood fl ow, central venous dialysis catheter was inserted into the lower third of vena cava superior. Apheresis was carried out on two types of apheresis devices available at the site, either on Cobe Spectra version 7.0 (Terumo BCT, Lakewood, Co) or on Amicus version 2.5 (Baxter, Deerfi eld, IL). As the anticoagulant solution, ACD (Acid citrate-dextrose solution) was used. In case of standard volume leukapheresis, the inlet to ACD ratio was of 12:1. Large volume leukapheresis was performed with the inlet to ACD ratio of 24:1, moreover, heparin was added to the ACD solution (3000 IU Heparin/500 mL ACD) and to collection bag (2000 IU Heparin).
Data evaluation
Collection (and harvest) characteristics were evaluated with regard to type of apheresis machine (Amicus vs Cobe Spectra), venous access (peripheral vein vs central venous catheter), and type of apheresis regimen (standard volume leukapheresis vs large volume leukapheresis). Totally 144 collection procedures were performed with Cobe Spectra and 25 procedures with Amicus, 122 procedures were performed using peripheral venous access (PV) and 47 procedures via central venous catheter (CVC). Effect of apheresis regimen type was analysed in 144 procedures performed by Cobe Spectra: 53 were standard volume leukapheresis (SVL) and 91 were large volume leukapheresis (LVL). Large volume leukapheresis was defi ned as processing individual´s total blood volume (TBV) more than three times during the procedure. Total blood volume calculation was based on Nadler's formula. Collected cell yields (CD34+ cells, white blood cells -WBC, mononuclear cells -MNC, colony forming units -CFU) were calculated in absolute numbers and per kilogram of recipient's body weight. Collection effi ciency for CD34+ cells (CE CD34) has been defi ned as the number of CD34+ cells collected per volume processed at a given circulating CD34+ cell count (11) . Assessment of product's contamination with red blood cells (RBC) was based on product's hematocrit (HTC). Product contamination with platelets (CE PLT) has been defi ned as the number of PLT collected per volume processed at a given circulating PLT count.
Statistical analysis
Statistical analyses were performed using SPSS version 16.0 for Windows. Data were analysed and compared for statistically signifi cant differences applying different tests in accordance to their characteristics and normality distribution. The 95 % confidence interval and the signifi cance level of 0.05 were set. Data are presented as median, minimum and maximum value.
Results
Effect of apheresis machine and venous access on procedure and harvest characteristics was evaluated in multivariable analysis. Subjects characteristics and pre-run parameters are detailed in Table 3 . Results of analyses are shown in Tables 4 and 5 .
Procedures performed with the apheresis machine Cobe Spectra were further assessed with regard to apheresis regimen (Tabs 6 and 7), focusing subsequently on LVL performance in "poor-mobilizers", defi ned as subjects with low pre-run CD34+ cell count in peripheral blood, i.e. < 20×10 6 /L (3, 15) . Procedure and harvest characteristics are detailed in Table 8 .
Discussion
In the past, several studies were realised comparing PBSC collection features with regard to different apheresis machines, often with contradictory results. In our study, with Cobe Spectra it was possible to process larger blood volumes per procedure (16. important virtue of Amicus was confi rmed also in other studies (2, 14) . Consequently, the use of Amicus is preferable in patients with severe trombocytopenia. Except the obvious benefi ts of central venous catheter usage (e.g. lower risk of insuffi cient blood fl ow and procedure interruption), the biggest detected advantage was the possibility to perform the procedure with higher fl ow rate (71 mL/min vs 89 mL/ min, r = 8.02, p = 0.0052), thus processing larger blood volume per unit of time. There was not statistically signifi cant difference in the CD34+ cell collection effi ciency. Nevertheless, interesting fi nding is the tendency to lower harvest PLT contamination when CVC is used (15.9 % vs 13.5 %, r = 3.77, p = 0.054). Therefore, CVC usage helps to limit post-procedural decrease in patient´s PLT count. This can be particularly benefi cial in subjects with initial pre-run thrombocytopenia, especially in case of LVL performance.
Large volume leukapheresis, by processing of larger blood volume (11.5 L vs 19.7 L, p < 0.0001) together with higher CD34+ cell collection effi ciency (CE CD34: 38.4 % vs 41.1 %, p = 0.02), enabled to reach signifi cantly higher HSCs yields when compa- red to SVL (in absolute numbers and per kilogram of recipient´s weight; p-value < 0.05 in all parameters). Higher cell yields in LVL procedures were confi rmed also in other studies (1, 13) . In addition, the harvest contamination with PLT was lower (CE PLT: 17.9 % vs 14.9 %, p < 0.0001). However, processing larger blood volume led to bigger postprocedural decrease in subject´s PLT count (39.9 % vs 48.3 %, p = 0.005), thus LVL may represent a considerable risk in patients with initial severe thrombocytopenia. Focusing on "poor mobilizers", there were no differences in collection effi ciency and product contamination when SVL and LVL procedures were compared, but statistically signifi cantly higher HSCs yields were reached in LVL procedures. Although there are discussions, whether LVL is meaningful in "poor mobilizers" due to lower HSCs reserves in BM and subsequent different dynamics of HSCs effl ux into the peripheral blood during longlasting procedure, these results suggest that LVL leads to better collection outcome in this group of subjects what is consistent with results of several other studies (1, 4, 5) .
However, the difference is little and further remobilization with different mobilization strategy may lead to more satisfactory results without the need of LVL performance, e.g. remobilization with plerixafor in multiple myeloma and lymphoma patients (6) .
Conclusion
To improve and optimize HSCs mobilization and collection, recommendations, regulations and guidelines should be regularly updated respecting current knowledge and experience. Furthermore, results from this study confi rm the hypothesis that management of PBSC collection requires a particular approach in each subject, i.e. the collection should be institutionally and individually optimized. Naturally, in case of "good mobilizers" it can be possible to collect suffi cient CD34+ yields regardless the apheresis machine, apheresis regimen and venous access used. However, this individual approach is particularly useful in "poor mobilizers", when every variable affecting collection success can be decisive for its outcome.
Regarding the technical aspects of PBSC collection practice at the site, important facts were revealed, favouring the Cobe Spectra apheresis machine version 7.0, LVL and the usage of CVC when compared to Amicus apheresis machine version 2.5, SVL and peripheral venous access. In case of "poor mobilizers" it is advisable to collect PBSC cells with Cobe Spectra rather than with Amicus. If we consider to perform LVL procedure, special attention should be paid to patients with initially low PLT count. Negative aspects of LVL can be minimized by the use of CVC, which enables setting of higher fl ow rates, thus shortening the running time and making the procedure more comfortable for donor/patient. Furthermore, CVC helps to minimize postprocedural decrease in patient´s PLT count. The decision regarding CVC insertion or LVL performance should be made after careful consideration of possible risks and benefi ts. A relatively low number of subjects represents the main limitation to perform this study in a more complex manner, focusing on each particular subgroup of subjects that could further meliorate collection effi cacy.
